Drug Manufacturers Imposing Unlawful Limits on 340B Discounts

Monitor Mondays

A growing number of drug manufacturers are imposing unlawful limits on 340B discounts, according to a newly released report by 340B Health. Currently, up to 13 such companies “just say no” to discounts for prescription drugs sold to safety-net hospitals and dispensed through community pharmacies.

During the next live edition of Monitor Mondays, reporting on the findings of this new report released late last month will be Maureen Testoni, president and CEO for 340B Health. Testoni is expected to report on how these major manufacturers are having a deleterious impact on 340B hospitals, while at the same time possibly harming patients.

The 340B program, established in 1992, allows these 340B providers to purchase outpatient drugs at a reduced cost and to use those savings to be invested in patient care.

Other segments to be featured during the live broadcast include the following:

• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Bryon, will join the broadcast with his trademark segment.
• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds with another installment of his popular segment.
• Monday Focus: Mary Beth Pace, vice president of care management for Trinity Health, will report on the alarming staffing crisis among case management professionals in America’s hospitals.
• Legislative Update: Former Centers for Medicare & Medicaid Services (CMS) official Matthew Albright, now chief legislative affairs officer for Zelis, will report on the status of healthcare legislation associated with the current COVID-19 pandemic.
• SDoH Report: Tiffany Ferguson, a subject matter expert on the social determinants of health (SDoH), will report on the news that’s happening at the intersection of healthcare regulations and the SDoH.